Freeman Kevin D's Form 4 filing
Galectin Therapeutics Inc (GALT) · filed Oct 16, 2024
- Accession no.
- 0001133416-24-000056
- Filed
- Oct 16, 2024
- Trade date
- Oct 16, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $27.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Freeman Kevin DCIK 0001522478 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2024 | Common Stock | PPurchaseAcquired | +5,000 | $2.70 | +$13,500 | 33,469 | Direct | |
| Oct 16, 2024 | Common Stock | PPurchaseAcquired | +5,000 | $2.70 | +$13,500 | 80,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.